Stocks in play: StageZero Life Sciences Ltd.

Has entered into a capital commitment agreement with GEM Global Yield LLC SCS for a $25-million Capital Commitment ("CC"). Draw downs are at the Company's discretion and subject to the terms as described in detail in the Financing Terms below. Proceeds raised from the investment will be used for working capital and general corporate purposes but especially to expand collaborations with employers, clinic and healthcare systems, and the insurers who support them. StageZero Life Sciences Ltd. shares T.SZLS are trading unchanged at $0.08.

Read:

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates

• Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America

• Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You

• Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options